The Controlled Substances Act is the 1970 federal law that governs how drugs and certain chemicals are manufactured, distributed, prescribed, and possessed in the United States. It replaced a patchwork of earlier drug laws with a single framework that sorts substances into five schedules based on abuse potential, accepted medical use, and likelihood of dependence. Penalties for violating it range from a $1,000 fine for simple possession to life in prison for trafficking offenses that result in death.
The Five Federal Drug Schedules
The law divides controlled substances into five tiers defined by three criteria: abuse potential, medical utility, and dependence risk.1Office of the Law Revision Counsel. 21 USC 812 – Schedules of Controlled Substances The higher the schedule number, the lower the perceived danger.
Schedule I
Schedule I substances have a high potential for abuse, no currently accepted medical use, and lack accepted safety for use even under medical supervision. Heroin, LSD, and ecstasy are the most commonly cited examples. Because these drugs have no recognized medical application under federal law, they cannot be prescribed. Researchers who want to study them face additional DEA registration requirements.
Schedule II
Schedule II drugs also carry a high abuse potential but have an accepted medical use, sometimes with severe restrictions. Abuse can lead to severe psychological or physical dependence. Fentanyl, oxycodone, cocaine (used as a local anesthetic in certain medical procedures), methamphetamine, and Adderall all sit in this category. Since 2014, all hydrocodone combination products have also been classified as Schedule II after the DEA moved them up from Schedule III.2Federal Register. Schedules of Controlled Substances: Rescheduling of Hydrocodone Combination Products From Schedule III to Schedule II
Schedule III
Schedule III substances have less abuse potential than those in Schedules I and II, an accepted medical use, and may cause moderate or low physical dependence but potentially high psychological dependence. Anabolic steroids, ketamine, and testosterone are common examples.1Office of the Law Revision Counsel. 21 USC 812 – Schedules of Controlled Substances As of April 2026, FDA-approved marijuana products and state-licensed medical marijuana also fall into Schedule III under a new federal rule, discussed below.
Schedules IV and V
Schedule IV substances have a low abuse potential relative to Schedule III and limited dependence risk. Diazepam (Valium), alprazolam (Xanax), and zolpidem (Ambien) are frequently prescribed Schedule IV medications for anxiety and sleep disorders.
Schedule V represents the lowest level of federal control. These drugs consist primarily of preparations containing small amounts of narcotics. Cough preparations with less than 200 milligrams of codeine per 100 milliliters, the antidiarrheal Lomotil, and pregabalin (Lyrica) are typical examples.3United States Drug Enforcement Administration. Drug Scheduling
How a Drug Gets Placed on a Schedule
The Attorney General holds the power to add a substance to the federal schedules, move it between schedules, or remove it entirely.4Office of the Law Revision Counsel. 21 USC 811 – Authority and Criteria for Classification of Substances Before making that call, the law requires an evaluation of eight factors:
- Actual or relative potential for abuse
- Scientific evidence of pharmacological effects
- Current state of scientific knowledge about the substance
- History and current pattern of abuse
- Scope, duration, and significance of that abuse
- Risk to public health
- Likelihood of causing psychological or physical dependence
- Whether the substance is an immediate precursor to something already controlled
Among these, the question of whether a drug has a “currently accepted medical use” carries enormous weight. A substance that fails this test lands in Schedule I regardless of how its pharmacology compares to drugs in lower schedules. The DEA historically applied a narrow five-part test that closely tracked FDA approval, but a 2024 Department of Justice analysis concluded that interpretation was too restrictive. The broader inquiry asks whether licensed healthcare providers have widespread experience using the drug through state-authorized programs, and whether credible scientific evidence supports at least one medical application.
The DEA and HHS Both Have a Role
Scheduling a new substance is a two-agency process. The DEA, acting on behalf of the Attorney General, either initiates the evaluation on its own or responds to a petition from an outside party. Before any decision takes effect, the Secretary of Health and Human Services must provide a scientific and medical evaluation, typically conducted by the FDA. The Secretary’s findings on scientific and medical questions are binding on the Attorney General. The DEA cannot override HHS’s medical conclusions even if it disagrees.
Emergency Scheduling
When a new drug hits the street faster than the normal process can keep up, the Attorney General can temporarily place it into Schedule I to avoid an imminent threat to public safety. This emergency power has a lighter evidentiary bar: only three factors, not eight. A temporary scheduling order lasts two years from the date it takes effect, with a possible one-year extension if permanent scheduling proceedings are still underway. The DEA has used this tool repeatedly to target synthetic cannabinoids and novel fentanyl analogues.
The Federal Analogue Act
Even temporary scheduling can’t keep pace with every new street drug. The Federal Analogue Act treats any substance “substantially similar” to a Schedule I or II controlled substance as if it were Schedule I, so long as it is intended for human consumption.5Office of the Law Revision Counsel. 21 USC 813 – Treatment of Controlled Substance Analogues Courts consider how the substance is marketed, the gap between its price and what it claims to be, and whether the seller knew buyers would consume it. Labeling something “not for human consumption” alone isn’t enough to escape prosecution.
Marijuana’s Current Federal Status
For over fifty years, marijuana sat in Schedule I alongside heroin and LSD. That changed in April 2026, when the Department of Justice and DEA issued a final rule placing two categories of marijuana products into Schedule III: FDA-approved drug products containing marijuana, and marijuana products covered by a qualifying state medical marijuana license.6Federal Register. Schedules of Controlled Substances: Rescheduling of Food and Drug Administration Approved Products Containing Marijuana and Products Containing Marijuana Subject to a Qualifying State-Issued License The action followed a December 2025 executive order on expanding medical marijuana and cannabidiol research.7United States Department of Justice. Justice Department Places FDA-Approved Marijuana Products and Products Containing Marijuana Subject to a Qualifying State-Issued License in Schedule III
State-licensed medical marijuana businesses can now apply for DEA registration through an expedited pathway, using their existing state credentials as proof of authorization. Applicants who submit within 60 days of the rule’s publication may continue operating under their state licenses while the application is pending. The DOJ also initiated an expedited administrative hearing, scheduled for June 29, 2026, to consider whether to reschedule marijuana broadly from Schedule I to Schedule III.
Recreational marijuana remains a Schedule I substance under the CSA. The federal rescheduling only applies to medical marijuana sold under a qualifying state license. A business operating in a state that has legalized recreational use but lacks a conforming medical license still faces the same federal exposure it did before.
Prescription and Refill Rules by Schedule
The schedule a drug sits in directly determines how it can be prescribed and refilled. The rules for Schedule II are dramatically more restrictive than for Schedules III through V.
Schedule II
Refills of Schedule II prescriptions are flatly prohibited. Every fill requires a new written prescription signed by the prescribing practitioner.8eCFR. Controlled Substances Listed in Schedule II A practitioner can write multiple prescriptions at once for up to a 90-day supply, but each prescription must include the earliest date on which it can be filled, and state law must allow it.
Emergencies create a narrow exception. A pharmacist can dispense a Schedule II drug based on a phone call from a prescribing practitioner, but the quantity is limited to what the patient needs during the emergency. The prescriber must then deliver a written prescription within seven days, marked “Authorization for Emergency Dispensing.” If that paper never arrives, the pharmacist must notify the nearest DEA office.
Schedules III Through V
Schedules III, IV, and V allow refills, but with limits. A prescription can be refilled up to five times and expires six months after the date it was written, whichever comes first.9eCFR. Controlled Substances Listed in Schedules III, IV, and V After five refills or six months, the practitioner must issue a completely new prescription. A practitioner can authorize additional refills by phone on an existing prescription, but the total still cannot exceed five refills within the six-month window.
Telehealth
Under the Ryan Haight Act of 2008, a practitioner generally must conduct at least one in-person evaluation before prescribing a controlled substance remotely. Pandemic-era flexibility has been repeatedly extended. Through December 31, 2026, DEA-registered practitioners may prescribe Schedule II through V controlled substances via telemedicine without a prior in-person visit, provided the prescription is for a legitimate medical purpose.10Federal Register. Fourth Temporary Extension of COVID-19 Telemedicine Flexibilities for Prescription of Controlled Medications Once a practitioner does conduct an in-person evaluation, the Ryan Haight Act’s telehealth restrictions no longer apply to that specific patient relationship going forward.
Who Must Register With the DEA
Anyone who manufactures, distributes, or dispenses controlled substances must hold a DEA registration. The statutory framework creates separate categories for Schedule I and II manufacturers, Schedule III through V manufacturers, distributors, dispensing practitioners, and researchers.11Office of the Law Revision Counsel. 21 USC 823 – Registration Requirements Each applicant receives a unique DEA registration number.
Retail pharmacies, hospitals, and individual practitioners typically apply using DEA Form 224.12Drug Enforcement Administration Diversion Control Division. Registration Under the most recently published fee schedule, practitioner registration costs $888 for a three-year period, while manufacturers pay $3,699 annually.13Federal Register. Registration and Reregistration Fees for Controlled Substance and List I Chemical Registrants
The Attorney General can revoke or suspend a registration on several grounds: materially falsifying an application, a felony drug conviction under federal or state law, losing a state license, or committing acts inconsistent with the public interest.14Office of the Law Revision Counsel. 21 USC 824 – Denial, Revocation, or Suspension of Registration When failures create an imminent danger to public health or safety, the DEA can suspend a registration immediately rather than waiting for a hearing.
Federal Criminal Penalties
The penalty structure escalates based on two variables: the type of offense and the offender’s criminal history. The gap between simple possession and trafficking is enormous, and repeat offenders face mandatory minimums that judges cannot reduce.
Simple Possession
A first-time federal conviction for simple possession carries up to one year in prison and a minimum $1,000 fine. A second offense after one prior drug conviction raises the ceiling to two years, with a mandatory minimum of 15 days and a $2,500 minimum fine. A third or subsequent offense means 90 days to three years and at least $5,000 in fines.15Office of the Law Revision Counsel. 21 USC 844 – Penalties for Simple Possession Courts cannot suspend or defer these mandatory minimums. On top of fines, a convicted person can be ordered to pay the reasonable costs of the investigation and prosecution.
Manufacturing, Distribution, and Trafficking
Penalties for making, distributing, or possessing controlled substances with intent to distribute are far more severe and depend on the type and quantity of the drug.16Office of the Law Revision Counsel. 21 USC 841 – Prohibited Acts A For Schedule I and II substances, the law creates a tiered system:
- High quantities (for example, 1 kilogram or more of heroin, 5 kilograms or more of cocaine, 280 grams or more of crack cocaine): mandatory minimum of 10 years, up to life. A prior conviction for a serious drug felony or serious violent felony raises the floor to 15 years. Two or more prior convictions mean at least 25 years.
- Intermediate quantities (for example, 100 grams or more of heroin, 500 grams or more of cocaine, 28 grams or more of crack cocaine): mandatory minimum of 5 years, up to 40 years. A prior serious conviction raises the floor to 10 years with a life maximum.
- Lower quantities of Schedule I or II substances not meeting the thresholds above: up to 20 years, with no mandatory minimum for a first offense. A prior felony drug conviction raises the ceiling to 30 years.
Death or Serious Bodily Injury
When someone dies or suffers serious bodily injury from a distributed substance, the penalties jump. For drugs in the top two quantity tiers, the mandatory minimum becomes 20 years and the maximum is life. If the offender has a prior felony drug conviction and someone dies, the sentence is life imprisonment with no possibility of probation or parole. Even Schedule III violations carry a 15-year maximum when death or serious injury results, doubling to 30 years for repeat offenders.
Recordkeeping Violations
Recordkeeping violations carry civil penalties of up to $10,000 per violation, with higher penalties reaching $100,000 per violation for opioid manufacturers and distributors who fail to report suspicious orders or maintain effective diversion controls.17Office of the Law Revision Counsel. 21 USC 842 – Prohibited Acts B Registrants must also take a complete inventory of controlled substances on hand at least once every two years and keep records available for DEA inspection.18eCFR. 21 CFR 1304.11 – Inventory Requirements